Humanized mouse model of Rasmussen’s encephalitis supports the immune-mediated hypothesis

Rasmussen’s encephalitis (RE) is a chronic inflammatory brain disorder that causes frequent seizures and unilateral hemispheric atrophy with progressive neurological deficits. Hemispherectomy remains the only treatment that leads to seizure freedom for this refractory epileptic syndrome. The absence of an animal model of disease has been a major obstacle hampering the development of effective therapies. Here, we describe an experimental mouse model that shares several clinical and pathological features with the human disease. Immunodeficient mice injected with peripheral blood mononuclear cells from RE patients and monitored by video electroencephalography developed severe seizures of cortical origin and showed intense astrogliosis and accumulation of human IFN-&ggr;– and granzyme B–expressing T lymphocytes in the brain compared with mice injected with immune cells from control subjects. We also provide evidence for the efficacy of &agr;4 integrin blockade, an approved therapy for the treatment of multiple sclerosis and Crohn’s disease, in reducing inflammatory markers associated with RE in the CNS. This model holds promise as a valuable tool for understanding the pathology of RE and for developing patient-tailored experimental therapeutics.

[1]  D. Greiner,et al.  Humanized Mouse Models of Clinical Disease. , 2017, Annual review of pathology.

[2]  C. Larochelle,et al.  Focal disturbances in the blood–brain barrier are associated with formation of neuroinflammatory lesions , 2015, Neurobiology of Disease.

[3]  F. Jensen,et al.  Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances , 2014, The Lancet Neurology.

[4]  H. Oguni,et al.  Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood , 2013, Brain and Development.

[5]  H. Wiendl,et al.  Rasmussen encephalitis treated with natalizumab , 2013, Neurology.

[6]  C. Elger,et al.  Rasmussen encephalitis: Incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins , 2013, Epilepsia.

[7]  D. Greiner,et al.  Humanized mice for immune system investigation: progress, promise and challenges , 2012, Nature Reviews Immunology.

[8]  E. Haddad,et al.  Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc− mouse model , 2012, Bone Marrow Transplantation.

[9]  M. Prinz,et al.  Role of ninjurin‐1 in the migration of myeloid cells to central nervous system inflammatory lesions , 2011, Annals of neurology.

[10]  J. Salmon,et al.  Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2Rγ-/- mice: a promising model for studying human disease. , 2011, Arthritis and rheumatism.

[11]  J. Hunter,et al.  Dual pathology in Rasmussen's encephalitis: A study of seven cases and review of the literature , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[12]  J. Schramm,et al.  Treatment of Rasmussen encephalitis half a century after its initial description: Promising prospects and a dilemma , 2009, Epilepsy Research.

[13]  G. Deuschl,et al.  A case of Rasmussen encephalitis treated with rituximab , 2009, Nature Reviews Neurology.

[14]  A. Becker,et al.  CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. , 2009, Brain : a journal of neurology.

[15]  E. Haddad,et al.  A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. , 2007, Journal of the American Society of Nephrology : JASN.

[16]  C. Elger,et al.  Astrocytes are a specific immunological target in Rasmussen's encephalitis , 2007, Annals of neurology.

[17]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[18]  C. Elger,et al.  Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. , 2005, Brain : a journal of neurology.

[19]  Y. Hart Rasmussen's encephalitis. , 2004, Epileptic disorders : international epilepsy journal with videotape.

[20]  J. Cross,et al.  Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis , 2004, Neurology.

[21]  C. Elger,et al.  An open study of tacrolimus therapy in Rasmussen encephalitis , 2004, Neurology.

[22]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[23]  G. Broggi,et al.  Experience with immunomodulatory treatments in Rasmussen’s encephalitis , 2003, Neurology.

[24]  T. Yednock,et al.  Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin , 2003, American Journal of Gastroenterology.

[25]  R. Spreafico,et al.  Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures , 2002, Journal of Neuroimmunology.

[26]  C. Elger,et al.  Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis , 2002, Annals of neurology.

[27]  M. Pittet,et al.  Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells. , 2002, Blood.

[28]  J. Dichgans,et al.  GluR3 antibodies: Prevalence in focal epilepsy but no specificity for Rasmussen’s encephalitis , 2001, Neurology.

[29]  J. McNamara,et al.  GluR3 Autoantibodies Destroy Neural Cells in a Complement-Dependent Manner Modulated by Complement Regulatory Proteins , 2000, The Journal of Neuroscience.

[30]  J. McNamara,et al.  Immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen’s encephalitis , 1999, Neurology.

[31]  M. Levite,et al.  Autoimmunity to the glutamate receptor in mice--a model for Rasmussen's encephalitis? , 1999, Journal of autoimmunity.

[32]  I. Fleidervish,et al.  Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. , 1999, Journal of autoimmunity.

[33]  J. Leach,et al.  Improvement in adult-onset Rasmussen’s encephalitis with long-term immunomodulatory therapy , 1999, Neurology.

[34]  H. Vinters,et al.  Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. , 1997, Journal of immunology.

[35]  J. Crawford,et al.  An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. , 1996, Blood.

[36]  J. McNamara,et al.  Plasmapheresis in Rasmussen's encephalitis , 1996, Neurology.

[37]  S. Rogers,et al.  Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site , 1995, Neuron.

[38]  H. Otsubo,et al.  Chronic encephalitis and epilepsy (Rasmussen's encephalitis) , 1995, Neurology.

[39]  J. McNamara,et al.  Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. , 1994, Science.

[40]  D. Fish,et al.  Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy) , 1994, Neurology.

[41]  C. Benjamin,et al.  Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. , 1993, The Journal of clinical investigation.

[42]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.

[43]  D. Asher Virologic studies in chronic encephalitis , 1991 .

[44]  J. Girvin,et al.  Cytomegalovirus and Rasmussen's encephalitis , 1990, The Lancet.

[45]  M. Hammond,et al.  Chronic encephalitis, epilepsy, and cerebrovascular immune complex deposits , 1990, Annals of neurology.

[46]  G. F. Walter,et al.  EPSTEIN-BARR VIRUS IN BRAIN AND RASMUSSEN'S ENCEPHALITIS , 1989, The Lancet.

[47]  H. C. Price,et al.  ORAL BACTERIAL VACCINE AND COLDS , 1975, The Lancet.

[48]  T. Rasmussen,et al.  Focal seizures due to chronic localized encephalitis , 1958, Neurology.